Development of a real-time PCR-based method for the measurement of neutralizing antibody to interferon-beta in multiple sclerosis patients
Background Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system (CNS). In Hong Kong, the prevalence rates of MS is 4.8/100,000. First line disease modifying agent (DMA) type 1 interferon β (IFN-β) is the most commonly use therapy for relapsing and re...
Main Authors: | , |
---|---|
Language: | English |
Published: |
The University of Hong Kong (Pokfulam, Hong Kong)
2014
|
Subjects: | |
Online Access: | http://hdl.handle.net/10722/206488 |